Verastem Reports Dosing of Copiktra (duvelisib) in CPSC’s Chinese Study for Relapsed or Refractory Follicular Lymphoma

 Verastem Reports Dosing of Copiktra (duvelisib) in CPSC’s Chinese Study for Relapsed or Refractory Follicular Lymphoma

Verastem Reports Dosing of Copiktra (duvelisib) in CPSC’s Chinese Study for Relapsed or Refractory Follicular Lymphoma

Shots:

  • CPSC has dosed its first patients in a Chinese bridging study assessing Copiktra in patients with r/r FL
  • In Sept’2018, the companies signed an exclusive licensing agreement which allows CPSC to develop & commercialize Verastem’ Copiktra for all oncology indications in China. The study is expected to serve as a bridging study based on the safety & efficacy in Verastem’s P-II DYNAMO study
  • Copiktra is a PI3K inhibitor, the first approved dual inhibitor of PI3K-delta and PI3K-gamma in the US and has received the FDA’s approval for r/r CLL/SLL following two prior therapies in Sept’2018

Click here to­ read full press release/ article | Ref: Business wire | Image: Verastem

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post